Clinical trial
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and…
NCT00207168 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00207168 |
|---|---|
| Title | To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine |
| Official title | A Randomized, Multi-center, Open Label Study in Well Controlled Treatment-experienced HIV- Infected Patients to Assess Compliance With a Once-daily Regimen |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry Dohme Australia |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | AIDS |
| Intervention type | Behavioral |
| Interventions | Compliance |
| Enrollment | 120 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Apr 22, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: